Ratings Moves: ING,...
Health Care: Drugs
Repros Therapeutics Inc. (RPRX: NASDAQ)
$16.50 0.68 | 4.30%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -18.17M | -12.49M | -4.77M | -27.23M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.05M | 100.00K | -568.00K | 1.85M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 2.78M | 2.28M | 447.00K | 2.01M |
| Net Cash From Continuing Operations | -13.50M | -9.76M | -4.95M | -22.08M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -13.50M | -9.76M | -4.95M | -22.08M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -578.00K | -15.00K | -7.00K | -502.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -30.00K | -320.00K | -364.00K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -608.00K | -335.00K | -371.00K | -502.00K |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 33.75M | 11.71M | 6.39M | 5.00M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 33.75M | 11.71M | 6.39M | 5.00M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 19.65M | 1.61M | 1.07M | -17.58M |
Portfolios with RPRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- Contributor16 Small-Cap Stocks in Dang...
- ContributorUnder $5 Stocks at Risk of ...
- UserSUPRATRADE Top Day Trader A...
- UserMicrobanks
Latest RPRX Headlines from TheStreet
- FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids 05.22.13 | 08:05 pm
- Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results 05.10.13 | 09:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Repros Patent Problems Began When Harry Met Joe 05.09.13 | 08:05 am
- Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead Of Schedule 05.02.13 | 12:05 pm
- Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University 04.29.13 | 12:04 pm
- Repros To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference 04.29.13 | 11:04 am
- Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents 04.10.13 | 12:04 pm
- The Five Dumbest Things on Wall Street: April 5
04.05.13 | 06:04 am - Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex 03.28.13 | 12:03 pm
Press Releases for RPRX
- Repros® Announces Dismissal Of Class Action Lawsuits - Business Wire 03.03.11 | 05:03 pm
- Repros Therapeutics® Announces Pricing Of Public Offering Of Common Stock And Warrants - Business Wire 02.03.11 | 03:02 pm
- Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism - Business Wire 01.03.11 | 09:01 am
- Reanalysis By Outside Statistician Shows Androxal® Provides Statistically Significant Improvement In Testosterone Levels In Men With Male Hormone Levels ≤ 250 Ng/dL - Business Wire 12.28.10 | 09:12 am
- Vaginal Delivery Of Repros’® Proellex® Bypasses First Pass Liver Effects And Achieves Greater Signals Of Efficacy At Significantly Lower Exposure - Business Wire 12.27.10 | 09:12 am
- Repros® Therapeutics Submits Data To The FDA Supporting Morning Assessment Of Testosterone For Men Treated With Androxal® As Indicative Of Average And Maximum Levels Attained - Business Wire 12.23.10 | 11:12 am
- Repros® Therapeutics Prepares To Commence Dosing In Second Cohort In Low Dose Proellex® Study - Business Wire 12.16.10 | 12:12 pm
- Repros Therapeutics Inc.® Reports Third Quarter 2010 Financial Results And Provides Corporate Update - Business Wire 11.10.10 | 06:11 am
- Repros® Announces Reverse Stock Split Effective On Nasdaq October 15, 2010 - Business Wire 10.14.10 | 08:10 pm
- FDA Grants Type B Meeting To Be Held November 8, 2010 To Discuss Phase III Protocols For Androxal® - Business Wire 09.30.10 | 06:09 am
Partner Headlines for RPRX
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- A Pullback Would Be Healthy For Repros Therapeutics - Seeking Alpha 09.20.12 | 09:09 am
- Update on Repros' Androxal - Analyst Blog - NASDAQ 09.14.12 | 09:09 pm
- Update on Repros' Androxal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Earnings Miss at Repros - Analyst Blog - NASDAQ 08.17.12 | 06:08 pm
- A Closer Look At Repros Therapeutics - Seeking Alpha 07.29.12 | 07:07 am
- Four Biotechs to Watch Early This Week - Seeking Alpha 03.06.11 | 08:03 am
- UPDATE 1-Repros submits more testosterone drug data, shrs soar - Reuters 12.23.10 | 01:12 pm
